CD30 ligand in lymphoma patients with CD30+ tumors.

Younes, Anas; Consoli, Ugo; Snell, Virginia; Clodi, Katharina; Kliche, Kay Oliver; Palmer, J. Lynn; Gruss, HJ; Armitage, Richard J.; Thomas, Elaine K.; Cabanillas, F; Andreeff, Michael

doi:10.1200/jco.1997.15.11.3355

Cited by 55 publications

(37 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the soluble form of CD30 (sCD30) has been shown to be an indicator of disease activity and a predictor of prognosis (Nadali et al, 1994), which is in good agreement with our own unpublished observations. The CD30L is expressed on activated T-cells and has the ability to induce apoptosis in several CD30+ cell lines (Younes et al, 1997). Thus, the increase in sCD30 can decrease the availability of CD30L on peripheral blood effector lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function

et al. 1999

View full text Add to dashboard Cite

Summary Epstein-Barr virus (EBV) expression was investigated by immunohistochemistry (latent membrane protein 1 ) and in situ hybridization (EBV encoded RNA [EBER]) in biopsies from 95 patients with untreated Hodgkin's disease (HD). Tumour EBV status was related to EBV antibody titres, spontaneous and concanavallin A induced blood lymphocyte DNA synthesis, serum levels of soluble (s) CD4, sCD8, sCD25, sCD30, sCD54, β2-microglobulin, thymidine-kinase, routine chemistry, patient characteristics, complete remission and survival. The median follow-up time was 145 months (range 60-257). Tumour EBV-positive (n = 30; 33%) and negative (n = 62; 67%) patients did not differ with regard to sex, age, stage, presence of bulky disease or B-symptoms, remission rate or survival. The proportion of EBV+ cases was significantly higher among patients with mixed cellularity histopathology (58%) as compared to the nodular sclerosis subtype (18%; P < 0.001). The total white blood cell (WBC) counts were significantly lower in EBV+ patients (P < 0.01), who also had significantly higher levels of sCD54 (P < 0.02) and a tendency towards lower levels of sCD30 (P = 0.056). Patients in the tumour EBV+ group had significantly higher IgG antibody titres to restricted early antigen (EA-R) (P < 0.02). Hence, clinical features and outcome were not related to tumour EBV status. However, HD patients with EBV+ tumours had elevated sCD54 levels, higher antibody titres to EA-R and decreased total WBC counts. A potential causal relationship between EBV tumour status and these findings needs to be further explored.

show abstract

Section: Discussionmentioning

confidence: 99%

Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function

et al. 1999

View full text Add to dashboard Cite

show abstract

“…20 Expression of CD30L (protein or mRNA) has been reported in several types of hematologic malignancies, including chronic lymphocytic leukemia (CLL), follicular B-cell lymphoma, hairy cell leukemia, T-cell lymphoblastic lymphoma, and adult T-cell leukemia lymphoma. 14,19,21 Like many TNF receptors, CD30's cytoplasmic tail contains several TRAF-binding sequences that can bind TRAF-1, -2, -3, and -5. Both TRAF-2 and TRAF-5 have been implicated in CD30 activation of NF-B.…”

Section: Cd30 Receptor and Cd30l (Cd153)mentioning

confidence: 99%

“…13,14 Several studies have reported that an elevated level of serum sCD30 expression in patients with anaplastic large-cell lymphoma or Hodgkin disease is correlated with a poor prognosis, perhaps because a high level of sCD30 reflects a high tumor burden or because sCD30L may block the biologic effects of CD30L. 14 -17 CD30L (CD153) is a type II transmembrane protein that belongs to the TNFSF.…”

Section: Cd30 Receptor and Cd30l (Cd153)mentioning

confidence: 99%

See 1 more Smart Citation

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders

Younes

Aggarwall

2003

Cancer

View full text Add to dashboard Cite

show abstract

“…The extracellular domain of CD30 can be cleaved and shed as a result of cellular activation (37). Soluble levels of CD30 are elevated and are associated with the prognosis in Hodgkin's disease and AIDS (38).…”

mentioning

confidence: 99%

Extremely Rapid and Intense Induction of Apoptosis in Human Eosinophils by Anti-CD30 Antibody Treatment In Vitro

Matsumoto

Terakawa

Miura

et al. 2004

The Journal of Immunology

View full text Add to dashboard Cite

Apoptosis is an important cellular mechanism for controlling cell viability and proliferation. With respect to eosinophils, cytokines prolong their survival, whereas corticosteroids reduce their survival in vitro. CD30, a member of the TNFR family, is expressed on the surface of many cell types, including Hodgkin’s lymphoma cells. CD30 is capable of inducing apoptosis after Ab treatment in some cell lines. To determine whether this surface structure is involved in apoptosis of human eosinophils, we examined its expression and the effect of anti-CD30 Ab treatment on the viability of eosinophils. Purified human eosinophils expressed low, but consistently detectable, levels of CD30. Immobilized, but not soluble, forms of anti-CD30 Abs (HRS-4 and Ber-H8) or recombinant mouse CD30 ligand exhibited an extremely rapid and intense survival-reducing effect on the eosinophils in the presence of exogenous IL-5; this effect was both concentration and time dependent. Furthermore, high concentrations of IL-5 could not reverse the reduced survival rates. After treatment with anti-CD30 Ab, gel electrophoresis of DNA extracted from the eosinophils demonstrated changes consistent with apoptosis. The immobilized F(ab′)2 of the anti-CD30 Ab failed to induce eosinophil apoptosis. The addition of anti-CD18 Ab also completely abrogated the induction of eosinophil apoptosis. Further examination using specific signal transduction inhibitors suggested the involvement of p38, mitogen-activated protein kinase kinase 1/2, and specific tyrosine kinase, but not NF-κB, in the induction of CD30-mediated eosinophil apoptosis. These data demonstrate that CD30 can modify eosinophil survival by causing an extremely rapid and intense induction of apoptosis through a tightly regulated intracellular signaling pathway.

show abstract

CD30 ligand in lymphoma patients with CD30+ tumors.

Cited by 55 publications

References 19 publications

Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function

Epstein–Barr virus expression in Hodgkin’s disease in relation to patient characteristics, serum factors and blood lymphocyte function

Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders

Extremely Rapid and Intense Induction of Apoptosis in Human Eosinophils by Anti-CD30 Antibody Treatment In Vitro

Contact Info

Product

Resources

About